Top

Published in:

01-12-2020 | Prostate Cancer | Special Section: Prostate cancer update

Comparison of biopsy strategies for prostate biopsy according to lesion size and PSA density in MRI-directed biopsy pathway

Published in: Abdominal Radiology | Issue 12/2020

Abstract

Purpose

To investigate whether the detection of clinically significant prostate cancer (csPCa) and the added value of focal saturation biopsy and systematic biopsy (SBx) differ according to index lesion size, and to compare the current guidelines for csPCa detection.

Methods

This retrospective study included consecutive men who underwent MRI and subsequent SBx and MRI-targeted biopsy (TBx) for a suspicious lesion between April 2019 and February 2020. Lesion visibility on transrectal ultrasound (US) and added value of focal saturation biopsy and SBx were compared according to index lesion size using chi-square and McNemar tests. csPCa detection rates and the proportion of biopsy-indicated men were compared among four biopsy strategies based on current guidelines.

Results

Of 313 men evaluated (median age, 65; interquartile range 60‒71), csPCa was detected in 110 (35%). In lesions < 10 mm, greater US invisibility (42.7% of lesions < 10 mm versus 20.0% of lesions ≥ 10 mm; p < 0.001) and higher added value of focal saturation biopsy and SBx (11.1% and 17.1% in lesions < 10 mm versus 4.2% and 6.3% in lesions ≥ 10 mm) were observed, compared with lesions ≥ 10 mm. Consideration of prostate-specific antigen (PSA) density > 0.15 ng/mL/mL as a cutoff in unsuspicious MRI led to a 14% reduction (44/313) in men who needed biopsy.

Conclusion

Determination of the biopsy strategy in terms of the need for focal saturation biopsy or SBx should be made considering lesion size. The use of PSA density in non-suspicious MRI can lead to a reduction in biopsy-indicated men.

Graphic abstract

Available only for authorised users

Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet 389 (10071):815–822. https://doi.org/10.1016/S0140-6736(16)32401-1CrossRef

Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM (2018) MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med 378 (19):1767–1777. https://doi.org/10.1056/NEJMoa1801993CrossRefPubMed

Kasivisvanathan V, Stabile A, Neves JB, Giganti F, Valerio M, Shanmugabavan Y, Clement KD, Sarkar D, Philippou Y, Thurtle D, Deeks J, Emberton M, Takwoingi Y, Moore CM (2019) Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 76 (3):284–303. https://doi.org/10.1016/j.eururo.2019.04.043CrossRefPubMed

Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, Tempany CM, Choyke PL, Cornud F, Margolis DJ, Thoeny HC, Verma S, Barentsz J, Weinreb JC (2019) Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. European Urology 76 (3):340-351. https://doi.org/10.1016/j.eururo.2019.02.033CrossRefPubMed

Hamid S, Donaldson IA, Hu Y, Rodell R, Villarini B, Bonmati E, Tranter P, Punwani S, Sidhu HS, Willis S, van der Meulen J, Hawkes D, McCartan N, Potyka I, Williams NR, Brew-Graves C, Freeman A, Moore CM, Barratt D, Emberton M, Ahmed HU (2019) The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification. European Urology 75 (5):733-740. https://doi.org/10.1016/j.eururo.2018.08.007CrossRefPubMedPubMedCentral

Padhani AR, Barentsz J, Villeirs G, Rosenkrantz AB, Margolis DJ, Turkbey B, Thoeny HC, Cornud F, Haider MA, Macura KJ, Tempany CM, Verma S, Weinreb JC (2019) PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway. Radiology 292 (2):464–474. https://doi.org/10.1148/radiol.2019182946CrossRefPubMed

Pepe P, Garufi A, Priolo GD, Galia A, Fraggetta F, Pennisi M (2018) Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy. J Urol 200 (4):774–778. https://doi.org/10.1016/j.juro.2018.04.061CrossRefPubMed

Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, Okoro C, Raskolnikov D, Parnes HL, Linehan WM, et al. (2015) Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA - journal of the american medical association 313 (4):390‐397. https://doi.org/10.1001/jama.2014.17942CrossRefPubMed

Rouviere O, Puech P, Renard-Penna R, Claudon M, Roy C, Mege-Lechevallier F, Decaussin-Petrucci M, Dubreuil-Chambardel M, Magaud L, Remontet L, Ruffion A, Colombel M, Crouzet S, Schott AM, Lemaitre L, Rabilloud M, Grenier N (2019) Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol 20 (1):100–109. https://doi.org/10.1016/s1470-2045(18)30569-2CrossRefPubMed

10.

Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, Bloom J, Gurram S, Siddiqui M, Pinsky P, Parnes H, Linehan WM, Merino M, Choyke PL, Shih JH, Turkbey B, Wood BJ, Pinto PA (2020) MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. New England Journal of Medicine 382 (10):917-928. https://doi.org/10.1056/NEJMoa1910038CrossRefPubMedPubMedCentral

11.

N. Mottet (Chair) RCNvdB, E. Briers (Patient Representative), P. Cornford (Vice-chair), M. De Santis, S. Fanti, S. Gillessen, J. Grummet, A.M. Henry, T.B. Lam, M.D. Mason, T.H. van der Kwast, H.G. van der Poel, O. Rouvière, D. Tilki, T. Wiegel, Guidelines Associates: T. Van den Broeck MC, N. Fossati, T. Gross, M. Lardas, M. Liew, L. Moris, I.G. Schoots, P-P.M. Willemse (2019) EAU guideline. 2019. Prostate cancer. https://uroweb.org/guideline/prostate-cancer/. Accessed March 3, 2020

12.

Guideline NIfHaCEN (2019) Prostate cancer: diagnosis and management (version 2019). https://www.nice.org.uk/guidance/ng131/chapter/Recommendations#assessment-and-diagnosis. Accessed July 1, 2020

13.

Rosenkrantz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, Haider MA, Margolis DJ, Marks LS, Pinto P, Sonn GA, Taneja SS (2016) Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol 196 (6):1613–1618. https://doi.org/10.1016/j.juro.2016.06.079CrossRefPubMedPubMedCentral

14.

National Comprehensive Cancer Network (2019) Prostate cancer early detection recommendations. https://jnccn.org/view/journals/jnccn/14/5/article-p509.xml.

15.

Baco E, Rud E, Eri LM, Moen G, Vlatkovic L, Svindland A, Eggesbø HB, Ukimura O (2016) A Randomized Controlled Trial To Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy. European urology 69 (1):149‐156. https://doi.org/10.1016/j.eururo.2015.03.041CrossRefPubMed

16.

Elkhoury FF, Felker ER, Kwan L, Sisk AE, Delfin M, Natarajan S, Marks LS (2019) Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study. JAMA Surgery. https://doi.org/10.1001/jamasurg.2019.1734CrossRefPubMedPubMedCentral

17.

Padhani AR, Weinreb J, Rosenkrantz AB, Villeirs G, Turkbey B, Barentsz J (2019) Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. Eur Urol 75 (3):385–396. https://doi.org/10.1016/j.eururo.2018.05.035CrossRefPubMed

18.

Gaziev G, Wadhwa K, Barrett T, Koo BC, Gallagher FA, Serrao E, Frey J, Seidenader J, Carmona L, Warren A, Gnanapragasam V, Doble A, Kastner C (2016) Defining the learning curve for multiparametric magnetic resonance imaging (MRI) of the prostate using MRI-transrectal ultrasonography (TRUS) fusion-guided transperineal prostate biopsies as a validation tool. BJU International 117 (1):80–86. https://doi.org/10.1111/bju.12892CrossRefPubMed

19.

Meng X, Rosenkrantz AB, Huang R, Deng FM, Wysock JS, Bjurlin MA, Huang WC, Lepor H, Taneja SS (2018) The Institutional Learning Curve of Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy: Temporal Improvements in Cancer Detection in 4 Years. Journal of Urology 200 (5):1022-1029. https://doi.org/10.1016/j.juro.2018.06.012CrossRefPubMed

20.

Hansen NL, Barrett T, Lloyd T, Warren A, Samel C, Bratt O, Kastner C (2019) Optimising the number of cores for magnetic resonance imaging-guided targeted and systematic transperineal prostate biopsy. BJU International. https://doi.org/10.1111/bju.14865CrossRefPubMed

21.

Martin PR, Cool DW, Romagnoli C, Fenster A, Ward AD (2014) Magnetic resonance imaging-targeted, 3D transrectal ultrasound-guided fusion biopsy for prostate cancer: Quantifying the impact of needle delivery error on diagnosis. Medical physics 41 (7):073504. https://doi.org/10.1118/1.4883838CrossRefPubMed

22.

Augustin H, Graefen M, Palisaar J, Blonski J, Erbersdobler A, Daghofer F, Huland H, Hammerer PG (2003) Prognostic significance of visible lesions on transrectal ultrasound in impalpable prostate cancers: implications for staging. J Clin Oncol 21 (15):2860–2868. https://doi.org/10.1200/jco.2003.11.130CrossRefPubMed

23.

Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, Margolis D, Schnall MD, Shtern F, Tempany CM, Thoeny HC, Verma S (2016) PI-RADS Prostate Imaging Reporting and Data System: 2015, Version 2. European Urology 69 (1):16-40. https://doi.org/10.1016/j.eururo.2015.08.052CrossRefPubMed

24.

Distler FA, Radtke JP, Bonekamp D, Kesch C, Schlemmer HP, Wieczorek K, Kirchner M, Pahernik S, Hohenfellner M, Hadaschik BA (2017) The Value of PSA Density in Combination with PI-RADS for the Accuracy of Prostate Cancer Prediction. J Urol 198 (3):575–582. https://doi.org/10.1016/j.juro.2017.03.130CrossRefPubMed

25.

Puech P, Rouviere O, Renard-Penna R, Villers A, Devos P, Colombel M, Bitker MO, Leroy X, Mege-Lechevallier F, Comperat E, Ouzzane A, Lemaitre L (2013) Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy–prospective multicenter study. Radiology 268 (2):461–469. https://doi.org/10.1148/radiol.13121501CrossRefPubMed

26.

Rais-Bahrami S, Türkbey B, Rastinehad AR, Walton-Diaz A, Hoang AN, Siddiqui MM, Stamatakis L, Truong H, Nix JW, Vourganti S, Grant KB, Merino MJ, Choyke PL, Pinto PA (2014) Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up. Diagnostic and interventional radiology (Ankara, Turkey) 20(4):293–298. https://doi.org/10.5152/dir.2014.13319CrossRef

27.

Ploussard G, Beauval JB, Renard-Penna R, Lesourd M, Manceau C, Almeras C, Gautier JR, Loison G, Portalez D, Salin A, Soulie M, Tollon C, Malavaud B, Roumiguie M (2020) Assessment of the Minimal Targeted Biopsy Core Number per MRI Lesion for Improving Prostate Cancer Grading Prediction. Journal of clinical medicine 9 (1). https://doi.org/10.3390/jcm9010225

28.

Mannaerts CK, Wildeboer RR, Postema AW, Hagemann J, Budäus L, Tilki D, Mischi M, Wijkstra H, Salomon G (2018) Multiparametric ultrasound: Evaluation of greyscale, shear wave elastography and contrast-enhanced ultrasound for prostate cancer detection and localization in correlation to radical prostatectomy specimens. BMC Urology 18 (1). https://doi.org/10.1186/s12894-018-0409-5

29.

Mehralivand S, Bednarova S, Shih JH, Mertan FV, Gaur S, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B (2017) Prospective Evaluation of PI-RADS™ Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System. Journal of Urology 198 (3):583-590.https://doi.org/10.1016/j.juro.2017.03.131CrossRefPubMedPubMedCentral

30.

van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M, Zamecnik P, Bakker D, Setiasti AY, Veltman J, van den Hout H, van der Lelij H, van Oort I, Klaver S, Debruyne F, Sedelaar M, Hannink G, Rovers M, Hulsbergen-van de Kaa C, Barentsz JO (2019) Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study(Figure presented.). European Urology 75 (4):570–578. https://doi.org/10.1016/j.eururo.2018.11.023

31.

Park SY, Park BK (2019) Necessity of differentiating small (< 10 mm) and large (≥ 10 mm) PI-RADS 4. World Journal of Urology. https://doi.org/10.1007/s00345-019-02924-2CrossRefPubMed

32.

Sheth S, Hamper UM, Walsh PC, Holtz PM, Epstein JI (1991) Stage A adenocarcinoma of the prostate: transrectal US and sonographic-pathologic correlation. Radiology 179 (1):35–39. https://doi.org/10.1148/radiology.179.1.2006300CrossRefPubMed

33.

Garcia-Reyes K, Nguyen HG, Zagoria RJ, Shinohara K, Carroll PR, Behr SC, Westphalen AC (2018) Impact of Lesion Visibility on Transrectal Ultrasound on the Prediction of Clinically Significant Prostate Cancer (Gleason Score 3 + 4 or Greater) with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Biopsy. J Urol 199 (3):699–705. https://doi.org/10.1016/j.juro.2017.09.075CrossRefPubMed

34.

Ukimura O, Marien A, Palmer S, Villers A, Aron M, de Castro Abreu AL, Leslie S, Shoji S, Matsugasumi T, Gross M, Dasgupta P, Gill IS (2015) Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies. World J Urol 33 (11):1669-1676.. https://doi.org/10.1007/s00345-015-1501-zCrossRefPubMed

35.

Rifkin MD, McGlynn ET, Choi H (1989) Echogenicity of prostate cancer correlated with histologic grade and stromal fibrosis: endorectal US studies. Radiology 170 (2):549-552 https://doi.org/10.1148/radiology.170.2.2643148CrossRefPubMed

36.

Deniffel D, Zhang Y, Salinas E, Satkunasivam R, Khalvati F, Haider MA (2020) Reducing Unnecessary Prostate Multiparametric Magnetic Resonance Imaging by Using Clinical Parameters to Predict Negative and Indeterminate Findings. Journal of Urology 203 (2):292-298. https://doi.org/10.1097/JU.0000000000000518CrossRefPubMed

Title: Comparison of biopsy strategies for prostate biopsy according to lesion size and PSA density in MRI-directed biopsy pathway
Publication date: 01-12-2020
Keywords: Prostate Cancer
Prostate Cancer
Published in: Abdominal Radiology / Issue 12/2020
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-020-02667-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Comparison of biopsy strategies for prostate biopsy according to lesion size and PSA density in MRI-directed biopsy pathway

Abstract

Purpose

Methods

Results

Conclusion

Graphic abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Graphic abstract

Please log in to get access to this content

Other articles of this Issue 12/2020

Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of 68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer

Robotic-assisted transrectal MRI-guided biopsy. Technical feasibility and role in the current diagnosis of prostate cancer: an initial single-center experience

SAR Prostate Cancer Disease-Focused Panel report

Quality Comparison of 3 Tesla multiparametric MRI of the prostate using a flexible surface receiver coil versus conventional surface coil plus endorectal coil setup

New prostate MRI techniques and sequences

Tips to start an MR-US fusion biopsy program

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page